It has been an amazing week in the field of stem cell technology with five big stories hitting the news all at once. New doors of therapeutic promise are opening whilst at the same time other doors are slamming shut... But the speed of new developments has increased by leaps and bounds just in the last few days.

Stem cells are naturally occurring cells in the body which have the capacity to develop into a variety of specialist cells. They have been recognized for well over a decade as having huge potential in the treatment of diseases where is there is tissue or cell loss-such as diabetes, Parkinson's disease, spinal injury, and heart disease.

The reason embryonic stem cells are so controversial is that the harvesting of embryonic stem cells involves the destruction of existing embryos and yet some American scientists have for years maintained that they are essential for research.

On the other hand, other scientists have argued that adult stem cells are safer than embryonic stem cells and have greater therapeutic potential.  Both adult stem cells (from bone marrow and other body tissues) and umbilical stem cells are already used in treatment for a wide variety of hematological and other conditions and over 100 diseases around the world. By contrast the first clinical trial using embryonic stem cells has only just recently begun and just as quickly ended.

Embryonic and "embryonic-like" iPS cells have problems of cysts, tumors, genetic anomalies of the donor and requirement of immunosuppressive drugs to mitigate rejection issues.

What has happened this week is that there have been some fantastic advances in using adult stem cells whilst at the same time a huge setback for or more specifically, the death of embryonic stem cell technology. These developments could be the first nail in the coffin for the misinformation and hype that the sick and dying American public have been fed by the FDA, AMA and Corporate-Controlled Media (CCM) on these issues for so long.

1. Let's be clear; for the first time in the "10 years behind the times" US medicine, adult stem cells from the patients' own body have been shown to improve heart failure.  Adult stem cells from the patients' own body have been shown to improve heart failure around the world since 2002.  To be clear, there have been earlier ASC successes in America, but none allowed to be publicized in Corporate-Controlled Media.

In the research carried out at the University of Louisville and published in the Lancet, the heart's blood-pumping efficiency in 14 patients who responded to the stem cell treatment, increased from 30.3% to 38.5% whilst at the same time the amount of dead heart muscle tissue decreased by 24% percent over four months. Seven control patients who did not receive the stem cell treatment showed no improvement.

2. In Europe, the doctors behind the world's first transplant of an artificial windpipe made from a patient's own stem cells are to begin clinical trials next year on a stem-cell 'bandage' for mending torn knee cartilage.

3. In Australia, embryonic-like stem cells have been isolated from breast milk in large numbers. The discovery raises the possibility of sourcing embryonic stem cells for regenerative medicine, without the need to destroy embryos.

Peter Hartmann at the University of Western Australia in Crawley and his colleagues first announced the discovery of stem cells in breast milk in 2008. [http://www.ncbi.nlm.nih.gov/pubmed/20712706] Now they have grown them in the lab and shown that they can turn into cells representative of all three embryonic germ layers, called the endoderm, mesoderm and ectoderm-a defining property of embryonic stem cells (ESC).

When "embryonic like" qualities are referenced, it refers to the ability of a stem cell to become all of the cells in the human body or pluripotency.  Adult stem cells with pluripotency are highly regarded because they can do everything an embryonic stem cell can do with none of the negative effects.  A number of pluripotent ADULT stem cells in the human body have been discovered thereby making embryonic and induced pluripotent stem cells (iPSC) for regenerative treatment 100% obsolete.  Adult stem cells derived from mother's milk are merely the latest to be recognized.

4. In Los Angeles, Scientists at the Mount Sinai School of Medicine have demonstrated that baby mice in utero can heal their mothers' heart disease (See 'Foetal stem cells "can repair mother's heart"'). They found that foetal stem cells from the placenta, which they had marked with green fluorescent protein, travelled to the pregnant mother's heart and were transformed into a variety of cells to repair cardiac damage. This may help to explain a phenomenon seen in previous studies where one in two women with peripartum cardiomyopathy spontaneously recovered after pregnancy. Imagine, adult stem cells from the fetus in a mother's womb can regenerate and heal illnesses in the mother's body. 

The director of cardiovascular regenerative medicine at the institution, Dr Hina Chaudhry, has described it as 'an exciting development that has far-reaching therapeutic potential'. The findings, which are published in the American Heart Association's journal Circulation Research, could help researchers find a stem cell treatment for heart disease.

5. Finally, the company doing the much-heralded first trial on embryonic stem cell therapy is discontinuing further stem cell work. See Geron Gives Up 

Geron, a pioneer in stem cell research that has been testing a potential spinal cord injury treatment, said late Monday that it's halting development of its eight different stem cell programs to conserve funds. It is seeking partners to take on the programs' assets and is laying off 66 staff, 38% of its entire workforce.

Those scientists who have been singing the praises of embryonic stem cells most loudly are, perhaps predictably, expressing their disappointment. The firm is claiming that its decision is 'purely financial' but John Martin, Professor of Cardiovascular Medicine at University College London has said: "The Geron trial had no real chance of success because of the design and the disease targeted. It was an intrinsically flawed study... The first trials of stem cell that will give an answer are our own in the heart. The heart is an organ that can give quantitative data of quality."

Josephine Quintavalle from the group CORE was rather more frank: "At long last after 10 years of unremitting hype, reality has caught up with embryonic stem cell claims. If Geron is abandoning this project it is because it is simply not working, despite the millions of dollars and hot air that has been invested in the promotion of this research."  Ms. Quintaville properly attacked Geron's claim of financial issues causing their dropping this hoax hot-potato, rather than the truth, which very well may be that one or more of the patients has suffered a typical result of ESC, such as cancer, or deadly immune rejection

So in summary, this has been a week where adult stem cell research has marched on whilst embryonic stem cell work has ground to a halt. What were perhaps always blind alleys are now closing but new highways of promise are opening ever and ever wider.

Source: